JP2017523205A - 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法 - Google Patents

共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法 Download PDF

Info

Publication number
JP2017523205A
JP2017523205A JP2017505509A JP2017505509A JP2017523205A JP 2017523205 A JP2017523205 A JP 2017523205A JP 2017505509 A JP2017505509 A JP 2017505509A JP 2017505509 A JP2017505509 A JP 2017505509A JP 2017523205 A JP2017523205 A JP 2017523205A
Authority
JP
Japan
Prior art keywords
solvent
pharmaceutically active
active compound
stream
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017505509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523205A5 (https=
Inventor
テムテム マルシオ
テムテム マルシオ
ペレイラ ルベン
ペレイラ ルベン
ヴィンセンテ ジョアン
ヴィンセンテ ジョアン
ガスペル フィリペ
ガスペル フィリペ
デュアルテ イリス
デュアルテ イリス
Original Assignee
ホビオネ インターナショナル エルティーディー
ホビオネ インターナショナル エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホビオネ インターナショナル エルティーディー, ホビオネ インターナショナル エルティーディー filed Critical ホビオネ インターナショナル エルティーディー
Publication of JP2017523205A publication Critical patent/JP2017523205A/ja
Publication of JP2017523205A5 publication Critical patent/JP2017523205A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0008—Sols of inorganic materials in water
    • B01J13/0013—Sols of inorganic materials in water from a precipitate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0093—Microreactors, e.g. miniaturised or microfabricated reactors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017505509A 2014-08-01 2015-07-31 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法 Pending JP2017523205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT107846 2014-08-01
PT10784614A PT107846B (pt) 2014-08-01 2014-08-01 Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
PCT/GB2015/052233 WO2016016665A1 (en) 2014-08-01 2015-07-31 A method of preparing amorphous solid dispersion in submicron range by co-precipitation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020124188A Division JP2020183426A (ja) 2014-08-01 2020-07-21 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法

Publications (2)

Publication Number Publication Date
JP2017523205A true JP2017523205A (ja) 2017-08-17
JP2017523205A5 JP2017523205A5 (https=) 2018-07-12

Family

ID=54011738

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017505509A Pending JP2017523205A (ja) 2014-08-01 2015-07-31 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP2020124188A Pending JP2020183426A (ja) 2014-08-01 2020-07-21 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP2022160657A Pending JP2023012459A (ja) 2014-08-01 2022-10-05 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP2024216106A Pending JP2025060664A (ja) 2014-08-01 2024-12-11 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020124188A Pending JP2020183426A (ja) 2014-08-01 2020-07-21 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP2022160657A Pending JP2023012459A (ja) 2014-08-01 2022-10-05 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP2024216106A Pending JP2025060664A (ja) 2014-08-01 2024-12-11 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法

Country Status (9)

Country Link
US (1) US20170209372A1 (https=)
EP (1) EP3174528A1 (https=)
JP (4) JP2017523205A (https=)
CN (2) CN107205931A (https=)
AU (1) AU2015295073B2 (https=)
CA (1) CA2956732C (https=)
IL (1) IL250372A0 (https=)
PT (1) PT107846B (https=)
WO (1) WO2016016665A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534897A (ja) * 2016-10-12 2019-12-05 キュリックス インコーポレイテッドＣｕｒｉｒｘ Ｉｎｃ． 治療薬の腸内送達のための製剤
JP2021080191A (ja) * 2019-11-18 2021-05-27 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP2021524845A (ja) * 2018-05-14 2021-09-16 キャプシュゲル・ベルジウム・エヌ・ヴィ 高い活性薬剤ローディングを有する固体剤形
JP2022510732A (ja) * 2019-02-18 2022-01-27 スレイバック・ファーマ・エルエルシー ニロチニブの医薬組成物
JP2023513045A (ja) * 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
JP2023513444A (ja) * 2020-01-24 2023-03-31 ナノコピーア リミテッド ライアビリティ カンパニー ダサチニブの非晶質固体分散体及びその使用
JP2023529777A (ja) * 2020-06-05 2023-07-12 アプライド マテリアルズ インコーポレイテッド 被覆薬物組成物及びその調製方法
JP2024037884A (ja) * 2018-06-15 2024-03-19 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878190B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878191B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020506905A (ja) * 2017-01-20 2020-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液
CN110494422A (zh) * 2017-03-15 2019-11-22 太阳制药先进研究有限公司 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
BR112021006821A2 (pt) 2018-10-12 2021-07-13 Hovione Scientia Limited método de tratamento de inflamação e patologias oftálmicas, dispersão sólida, formulação farmacêutica, método de matar ácaros e kit
KR102941878B1 (ko) * 2019-02-05 2026-03-23 린디 바이오사이언시스, 아이엔씨. 단리된 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
WO2021064123A1 (en) * 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide
WO2021072635A1 (zh) * 2019-10-15 2021-04-22 诸暨易联众创企业管理服务有限公司 一种棒状氯化亚铁纳米材料的制备方法
CN110693839B (zh) * 2019-11-19 2022-03-08 乐普药业股份有限公司 一种甲磺酸仑伐替尼固体分散体及其制备方法和用途
CN112933049B (zh) * 2019-11-26 2024-02-06 深圳微芯生物科技股份有限公司 含无定型态芳杂环化合物的组合物、其制备方法及用途
WO2021134647A1 (zh) * 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
EP3884930A1 (en) * 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
WO2021222739A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
EP4164618A4 (en) * 2020-06-10 2024-06-19 Board of Regents, The University of Texas System 3D LASER SINTERING PROCESS FOR IMPROVED ACTIVE INGREDIENT RELEASE
CN112121014A (zh) * 2020-08-19 2020-12-25 汕尾市前瞻高等理工研究院 一种制备稳定无定型药物固体制剂的方法
US20230414510A1 (en) * 2020-09-08 2023-12-28 Crititech, Inc. Niclosamide particles and uses thereof
MX2023003556A (es) * 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
PT117030B (pt) * 2021-01-25 2024-03-08 Hovione Farm S A Método de secagem de pós farmacêuticos
CN113069415B (zh) * 2021-04-09 2022-09-09 湖北中医药大学 难溶性药物纳米混悬剂及其制备方法
WO2023283616A1 (en) * 2021-07-09 2023-01-12 Regents Of The University Of Minnesota Amorphous solid dispersion of sorafenib and solid formualtion comprising the same
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
TW202444365A (zh) 2023-01-31 2024-11-16 漢達生技醫藥股份有限公司 改良之卡博替尼組合物及其使用方法
CN116688139B (zh) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 一种克唑替尼药物组合物及其制备方法和应用
US20260096994A1 (en) * 2024-10-07 2026-04-09 Boehringer Ingelheim International Gmbh Solid dispersions having stabilized emulsion particles
CN120919059B (zh) * 2025-10-15 2026-02-03 浙江奥翔药业股份有限公司 一种芦可替尼药物组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007224048A (ja) * 1998-09-22 2007-09-06 F Hoffmann La Roche Ag 低溶解性化合物の安定な複合体
JP2012530127A (ja) * 2009-06-19 2012-11-29 ドラッガビリティ テクノロジーズ アイピー ホールドコ （ジャージー） リミテッド ナノ粒子のカンデサルタンシレキセチル組成物、その調製方法及びそれらを含有する医薬組成物
JP2013528642A (ja) * 2010-06-18 2013-07-11 ドラッガビリティ テクノロジーズ アイピー ホールディングカンパニー（ジャージー）リミティド ナノ構造アプレピタント組成物、これらの調製のための方法、及びこれらを含む医薬組成物
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
JP2014508027A (ja) * 2010-12-21 2014-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ 噴霧乾燥技術
WO2014114575A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
WO2009118356A2 (en) * 2008-03-25 2009-10-01 Formac Pharmaceuticals N.V. Preparation method for solid disupersions
US8187554B2 (en) * 2008-04-23 2012-05-29 Microfluidics International Corporation Apparatus and methods for nanoparticle generation and process intensification of transport and reaction systems
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
CN201337903Y (zh) 2008-12-30 2009-11-04 河北科技大学 一种用于制备超细无定型头孢呋辛酯的微反应器
CN101507908B (zh) * 2009-04-09 2010-12-01 北京化工大学 微通道套管式装置及其应用
HUP1000327A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007224048A (ja) * 1998-09-22 2007-09-06 F Hoffmann La Roche Ag 低溶解性化合物の安定な複合体
JP2012530127A (ja) * 2009-06-19 2012-11-29 ドラッガビリティ テクノロジーズ アイピー ホールドコ （ジャージー） リミテッド ナノ粒子のカンデサルタンシレキセチル組成物、その調製方法及びそれらを含有する医薬組成物
JP2013528642A (ja) * 2010-06-18 2013-07-11 ドラッガビリティ テクノロジーズ アイピー ホールディングカンパニー（ジャージー）リミティド ナノ構造アプレピタント組成物、これらの調製のための方法、及びこれらを含む医薬組成物
JP2014508027A (ja) * 2010-12-21 2014-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ 噴霧乾燥技術
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2014114575A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534897A (ja) * 2016-10-12 2019-12-05 キュリックス インコーポレイテッドＣｕｒｉｒｘ Ｉｎｃ． 治療薬の腸内送達のための製剤
US12594246B2 (en) 2016-10-12 2026-04-07 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
JP7046081B2 (ja) 2016-10-12 2022-04-01 キュリックス インコーポレイテッド 治療薬の腸内送達のための製剤
JP2021524845A (ja) * 2018-05-14 2021-09-16 キャプシュゲル・ベルジウム・エヌ・ヴィ 高い活性薬剤ローディングを有する固体剤形
JP7333340B2 (ja) 2018-05-14 2023-08-24 キャプシュゲル・ベルジウム・エヌ・ヴィ 高い活性薬剤ローディングを有する固体剤形
JP7652454B2 (ja) 2018-06-15 2025-03-27 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
JP2024037884A (ja) * 2018-06-15 2024-03-19 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
JP2022510732A (ja) * 2019-02-18 2022-01-27 スレイバック・ファーマ・エルエルシー ニロチニブの医薬組成物
JP7211644B2 (ja) 2019-02-18 2023-01-24 スレイバック・ファーマ・エルエルシー ニロチニブの医薬組成物
JP7378279B2 (ja) 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP2021080191A (ja) * 2019-11-18 2021-05-27 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP2023513444A (ja) * 2020-01-24 2023-03-31 ナノコピーア リミテッド ライアビリティ カンパニー ダサチニブの非晶質固体分散体及びその使用
JP7738961B2 (ja) 2020-01-24 2025-09-16 ハンダ セラピューティクス リミテッド ライアビリティ カンパニー ダサチニブの非晶質固体分散体及びその使用
JP2023513045A (ja) * 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
JP2026053379A (ja) * 2020-01-31 2026-03-25 フレックス ファーマ リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
JP2023529777A (ja) * 2020-06-05 2023-07-12 アプライド マテリアルズ インコーポレイテッド 被覆薬物組成物及びその調製方法
JP7565375B2 (ja) 2020-06-05 2024-10-10 アプライド マテリアルズ インコーポレイテッド 被覆薬物組成物及びその調製方法

Also Published As

Publication number Publication date
JP2020183426A (ja) 2020-11-12
JP2025060664A (ja) 2025-04-10
IL250372A0 (en) 2017-03-30
WO2016016665A1 (en) 2016-02-04
JP2023012459A (ja) 2023-01-25
US20170209372A1 (en) 2017-07-27
AU2015295073B2 (en) 2019-12-19
PT107846B (pt) 2019-03-22
CA2956732C (en) 2022-11-22
CA2956732A1 (en) 2016-02-04
CN107205931A (zh) 2017-09-26
EP3174528A1 (en) 2017-06-07
CN117159474A (zh) 2023-12-05
AU2015295073A1 (en) 2017-02-23
PT107846A (pt) 2016-02-01

Similar Documents

Publication Publication Date Title
JP2023012459A (ja) 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
JP7203078B2 (ja) 粒子の連続製造方法
US12544378B2 (en) Solid pharmaceutical formulation of PARP inhibitors and use thereof
JP2009533357A (ja) 貧溶解性薬剤における、溶解度および溶解速度を向上させる方法
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
Tripathy et al. Solid dispersion: A technology for improving aqueous solubility of drug
WO2005065653A1 (en) Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
Nekkanti et al. Developing nanoparticle formulations of poorly soluble drugs
ES2988334T3 (es) Producción continua de partículas
AU2024209240A1 (en) Crystalline nanoparticles comprising enzalutamide
Ellenberger Processing challenging active pharmaceutical ingredients and polymers by Kinetisol to produce amorphous solid dispersions with improved in-vitro and in-vivo performance
Pillai Development and Characterization of Solid Dosage form Incorporating Camptothecin Analog Nanoparticles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200324

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200721

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200818

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200818

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20201006

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201013

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20201104

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201104